deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter

Nov 4, 2008 | NEWS

Reykjavik, ICELAND, November 4, 2008 – deCODE genetics (Nasdaq:DCGN) today announced today that it has requested a hearing before a Nasdaq Listing Qualifications Panel to present a plan for regaining compliance with Nasdaq Marketplace Rule 4450(b)(1)(A), which...

deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results

Oct 28, 2008 | NEWS

Reykjavik, ICELAND, October 28, 2008 – deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it will report its third quarter 2008 financial results in a press release to be issued on Thursday, November 6, after the close of the market in New York. The...

deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer

Oct 13, 2008 | NEWS

Latest discoveries add to understanding of individual risk of basal cell carcinoma, and are integrated into the deCODEme™ personal genome analysis scan Reykjavik, ICELAND, October 13, 2008 – Scientists at deCODE genetics (Nasdaq:DCGN) today report the discovery of...

deCODE Launches deCODE BreastCancer™, a Genetic Test to Screen for Risk of the Most Common Forms of Breast Cancer

Oct 8, 2008 | NEWS

Enables women to understand whether they may benefit from more intensive screening, monitoring or preventive drug therapy Reykjavik, ICELAND, October 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the launch of deCODE BreastCancer™, a new tool for assessing...

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer’s and Other Cognitive Disorders

Oct 3, 2008 | NEWS

Reykjavik, ICELAND, October 3, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the filing of an investigational new drug (IND) application for DG071, the company’s novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug...

deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer

Sep 14, 2008 | NEWS

Detection may be used to complement and target screening for the disease; variants will be integrated into the deCODEme™ personal genome scan. Reykjavik, ICELAND, September 14, 2008 – Scientists at deCODE genetics (Nasdaq:DCGN) and colleagues at Radboud University...